Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic nitroxoline for keratolytic winter erythema (randomized placebo-controlled crossover, Norwegian families)
2022-501726-38-00Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of nitroxoline in Keratolytic winter erythema (KWE) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Relative change in affected body surface area. Started Nov 2022; status: completed.
02
Drugs
nitroxoline
03
Conditions
Keratolytic winter erythema (KWE)
Beyond the preview
Go deeper on 2022-501726-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501726-38-00.